We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Similarity Found Between Wound Healing and Cancer Progression

By Biotechdaily staff writers
Posted on 27 Jan 2004
Researchers have found a similarity between the molecular programs in normal wound healing and tumor progression and metastasis, which suggests that a wound-like phenotype is a general risk factor for metastasis and aggressive behavior in many common cancers.

The idea that cancer cells go through a fateful transition into fast-growing, invasive, metastasizing tumors surfaced in the early 1970s. More...
By the mid-1980s, histologic analysis had revealed a similarity between the tumor microenvironment and that of a healing wound, but scientists had no way at that time to evaluate the risk that a wound-healing genetic program might pose in cancer progression.

In an effort to create a framework for evaluating the relationship between tumors and wounds, researchers have examined the gene expression profile of fiberblasts responding to serum in cell culture. Both fiberblasts and serum are involved in wound healing. Although the fiberblasts differed in their properties and gene expression profiles, they were found to share a common expression pattern in response to serum. From this expression profile, the researchers identified a core group of genes that comprise a genetic signature associated with a serum response.

Since many of the genes were involved in various wound-healing processes, the researchers used this signature as a surrogate marker to measure how much tumors may be like wounds. When they compared the genetic signature with expression patterns of various tumor samples, they found the signature was always present in prostate and liver cell cancer and occurred variably in breast, lung, and gastric cancers. Patients with these latter types of tumors carrying the serum response genetic signature had a significantly increased risk of metastasis and death, compared to patients without the signature.

Thus, the serum-response signature provides a valuable new diagnostic tool for predicting tumor behavior and determining a patient's prognosis, concluded Howard Chang and his colleagues in Patrick Brown's laboratory at Stanford University (Palo Alto, CA, USA). Their work was reported in the January 2, 2004, online issue of PloS (Public Library of Science).




Related Links:
Stanford

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.